Valuation: Penumbra, Inc.

Market Cap 12.79B 11.06B 10.33B 9.48B 17.82B 1,217B 18.11B 121B 47.57B 610B 48.02B 46.97B 2,017B P/E 2026 *
73.6x
P/E 2027 * 53x
Enterprise Value 12.34B 10.68B 9.97B 9.15B 17.2B 1,175B 17.47B 117B 45.91B 589B 46.34B 45.33B 1,946B EV / Sales 2026 *
7.74x
EV / Sales 2027 * 6.7x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day-0.06%
1 week+1.08%
Current month+1.08%
1 month+1.99%
3 months+0.00%
6 months-4.80%
Current year+4.42%
1 week 321.35
Extreme 321.35
325.74
1 month 315.69
Extreme 315.69
325.74
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
2/13/26 Free

Founder

589 0.0015%
2/13/26 Free

Director

589 0.0015%
2/13/26 Free

General Counsel

5,742 0.0146%
Change 5-day change 1-year change 3-year change Capi.($)
-0.06%+1.08%+34.86%+28.50% 12.79B
-0.29%-0.17%+21.63%+22.61% 6.81B
+0.79%+2.67%+57.15%+28.07% 6.21B
+6.41%+8.59% - - 5.5B
-0.58%-8.31%-25.19%+34.98% 4.36B
+1.30%-2.64%-22.77%-18.05% 4.04B
+4.46%+10.44%+42.40%-39.12% 1.91B
-0.51%-5.18%-15.07%+200.51% 1.75B
+3.67%+6.92%+68.57%+0.78% 1.71B
+2.97%+2.88%-28.22%-45.92% 1.3B
Average +1.82%+1.77%+14.82%+23.59% 4.64B
Weighted average by Cap. +1.25%+1.41%+21.54%+24.22%

Financials

2026 *2027 *
Net sales 1.6B 1.38B 1.29B 1.18B 2.22B 152B 2.26B 15.12B 5.93B 76.1B 5.99B 5.86B 252B 1.8B 1.56B 1.45B 1.33B 2.51B 171B 2.55B 17.06B 6.69B 85.85B 6.76B 6.61B 284B
Net income 176M 153M 143M 131M 246M 16.79B 250M 1.67B 656M 8.42B 663M 648M 27.82B 242M 210M 196M 180M 338M 23.06B 343M 2.3B 901M 11.56B 910M 890M 38.21B
Net Debt -447M -387M -361M -331M -623M -42.54B -633M -4.24B -1.66B -21.32B -1.68B -1.64B -70.49B -729M -630M -589M -540M -1.02B -69.35B -1.03B -6.91B -2.71B -34.76B -2.74B -2.68B -115B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-08-07 US$324.66 -0.06% 239,512
26-08-06 US$324.86 +0.51% 262,161
26-08-05 US$323.21 -0.31% 282,960
26-08-04 US$324.22 +0.37% 363,249
26-08-03 US$323.02 +0.57% 328,452
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
324.66USD
Average target price
361.83USD
Spread / Average Target
+11.45%

Quarterly revenue - Rate of surprise